Declaration of interests MPB is the Executive Director of the Colorado Prevention Center, a non-profit academic research organisation affiliated with the University of Colorado, that receives or has received research grant or consulting funding between August, 2021 and the present from: Abbott Laboratories, Agios Pharmaceuticals, Alexion Pharma, Alnylam Pharmaceuticals, Amgen, Angionetics, Anthos Therapeutics, Array BioPharma, AstraZeneca and Affiliates, Atentiv, Audentes Therapeutics, Bayer and Affiliates, Bristol Myers Squibb, Cambrian Biopharma, Cardiol Therapeutics, CellResearch, Cleerly, Cook Regentec, CSL Behring, Eidos Therapeutics, EP Trading, Epizon Pharma, Esperion Therapeutics, Everly Well, Exicon Consulting, Faraday Pharmaceuticals, Foresee Pharmaceuticals, Fortress Biotech, HDL Therapeutics, HeartFlow, Hummingbird Bioscience, Insmed, Ionis Pharmaceuticals, Janssen and Affiliates, Kowa Research Institute, Lexicon Pharmaceuticals, Medimmune, Merck and Affiliates, Nectero Medical, Novartis Pharmaceuticals, Novo Nordisk, Osiris Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Prairie Education and Research Cooperative, Prothena Biosciences, Regeneron Pharmaceuticals, Regio Biosciences, Sanofi-Aventis Group, Silence Therapeutics, Smith & Nephew, Stealth BioTherapeutics, VarmX, and Virta Health Corporation. A-MC is an employee of and owns shares in Novo Nordisk. KH has received payment or honoraria, along with travel support, to give a presentation at a workshop organised by LeMaitre. BL has received consulting fees, payment, or honoraria from Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; has received travel support from Novo Nordisk, with unpaid roles as a National Leader for the Novo Nordisk ESSENCE trial, a National Leader for the Eli Lilly Triumph-Outcome Study, and an advisor for an advisory board for the Austrian Obesity Society. JN has received payment or honoraria from Novo Nordisk; has received travel support from Philips Medical and Abbott; has served on advisory boards for AstraZeneca, Novo Nordisk, and iThera Medical; and has a research grant from the Swedish Heart and Lung Foundation 2021–26, with unpaid roles as President of the Swedish Society for Vascular Surgery and the Swedish Councillor for the European Society for Vascular Surgery 2020–23. CKR is an employee of and owns shares in Novo Nordisk. NR has served on advisory boards for Eli Lilly and Novo Nordisk, and has received research grants from Eli Lilly, Novo Nordisk, and Soma Scan. HS has received payment or honoraria from Amarin, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, and Novo Nordisk; has received travel support from Boehringer Ingelheim, Daiichi Sankyo, and Novo Nordisk; and has served on advisory boards for Eli Lilly and Novo Nordisk, with unpaid roles as a board member of the Austrian Diabetes Association. AV is an employee of Novo Nordisk. SV has received payment or honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management, Sanofi, and Sun Pharmaceuticals; has served on advisory boards for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, and Sanofi; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, and Sanofi.
PubMed
